Showing 1081-1090 of 1211 results for "".
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Clearside Biomedical Announces Multiple Poster Presentations at ARVOhttps://modernod.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/Clearside Biomedical announced that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- New Alcon Data on Contact Lens, Dry Eye, and Ocular Health to Be Presented at ARVO 2021https://modernod.com/news/new-alcon-data-on-contact-lens-dry-eye-and-ocular-health-to-be-presented-at-arvo-2021/2479151/Alcon will present new data on several of its latest contact lens, dry eye, and ocular health innovations during the Association for Research in Vision and Ophthalmology (ARVO) 2021 virtual meeting taking place May 1-7. Alcon boasts a robust scientific showing at the meeting with nine accepted ab
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Alcon Presents Highlights of ARVO 2021 Datahttps://modernod.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/Alcon will be presenting new data at the Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting (May 1-7). Presentations include data for the Systane iLux MGD Thermal Pulsation System, Precision1 daily disposable contact lenses, and a forthcoming reusable monthly contact lens